BioSpace News Archive

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore, “Propella”), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023.

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).

Myriad Genetics, Inc. today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024.

RenovoRx, Inc today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial.

Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 11, 2024.

NS Pharma, Inc. has granted orphan drug designation for NS-089/NCNP-02, which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne).

Kinaset Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference.

Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.